Skip to content
Open access

A primary human muscle cell-based assay for detecting myasthenia gravis autoantibody binding and assessing AChR cluster impairment

Aug 2026 · bioRxiv · 0 citations · 31 references
Biology

TL;DR

A physiologically relevant human NMJ model based on primary human muscle cells is established that enables detection and functional characterization of neuromuscular autoantibodies and a novel muscle cell-based assay (CBA) for the detection of neuromuscular autoantibodies is developed.

Abstract

Myasthenia gravis (MG) is an autoimmune disease caused by pathogenic autoantibodies against proteins at the neuromuscular junction (NMJ). The diagnosis and clinical management of MG patients largely relies on the detection of antigen-specific autoantibodies targeting acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). Yet a subset of patients remains seronegative for known MG autoantibodies, highlighting a critical need for alternative approaches to identify pathogenic NMJ antibodies. We established a new human in vitro model of the NMJ based on primary human muscle cells that recapitulates key features of the NMJ: differentiation to myotubes, expression of key NMJ proteins and formation of postsynaptic AChR clusters in response to agrin stimulation. The model allows new insights into myogenesis and genetic muscle diseases, and the new muscle cell-based assay (CBA) detected autoantibodies in sera from patients with AChR- and MuSK-positive MG with 96.43% sensitivity and 100% specificity, while healthy control sera showed no reactivity. Incubation with patient sera significantly reduced AChR clustering compared to controls, demonstrating functional pathogenic effects. Thus, we established a physiologically relevant human NMJ model that enables detection and functional characterization of neuromuscular autoantibodies. This novel approach addresses a key limitation of current antigen-specific diagnostics and provides a method for improved detection and characterization of MG antibodies, independent of antigen specificity. One Sentence Summary We established a postsynaptic human in vitro neuromuscular junction model to assess binding and pathogenicity of MG autoantibodies. Key messages What is already known on this topic? Current diagnosis of myasthenia gravis (MG) relies largely on the detection of antigen-specific autoantibodies against AChR and MuSK, leaving a clinically relevant subset of patients seronegative. What are the new findings? We established a physiologically relevant human in vitro neuromuscular junction model based on primary human muscle cells and developed a novel muscle cell-based assay (CBA) for the detection of neuromuscular autoantibodies. How might this impact on clinical practice or future developments? The CBA detected autoantibodies in patients with AChR- or MuSK-positive MG with high sensitivity and specificity and demonstrated their functional pathogenic effects on AChR clustering. This antigen-independent approach may improve the detection and functional characterization of MG autoantibodies, particularly in patients who are seronegative in current diagnostic assays.

Read PDF

Similar papers

Sep 2026

Accuracy of Antibody Testing in Myasthenia Gravis: The ADAM Study.

BACKGROUND AND OBJECTIVES Antibody testing has a pivotal role in the diagnosis of myasthenia gravis (MG). However, there are limited data on the accuracy of the different methods available for acetylcholine receptor (AChR) and muscle-specific kinase (MuSK) autoantibody (Ab) detection in a real-world setting. Our aim wa...

M. P. Giannoccaro, Lucrezia Serra, A. Grondona et al. · 0 citations
Open access Aug 2026

Bispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models

Myasthenia gravis (MG) is an autoimmune neuromuscular disorder mediated by autoantibodies targeting the nicotinic acetylcholine receptor (nAChR), which can lead to severe disability and life-threatening crises. Current therapies rely on broad immunosuppression and fail to achieve sustained remission in the majority of...

Niels von Wardenburg, G. Spagni, S. Reincke et al. · 0 citations
Review Sep 2026

Pathogenesis of autoantibodies in inflammatory myopathies.

PURPOSE OF REVIEW While autoantibodies targeting extracellular antigens, such as those in myasthenia gravis, are established mediators of disease, autoantibodies recognizing intracellular antigens in inflammatory myopathies have traditionally been considered nonpathogenic. This review examines evidence challenging that...

K. C. Chung, Qian-Zi Zhao, I. Pinal-Fernandez · 0 citations
Open access Sep 2026

Autoantibody Profiles of Immune Checkpoint Inhibitor-Associated Myasthenia and Myositis

Introduction Immune checkpoint inhibitor (ICI)-associated myasthenia and myositis are rare, potentially life-threatening neuromuscular immune-related adverse events, but their serological spectrum remains incompletely characterized. This study aimed to elucidate their autoantibody profiles and explore associations with...

T. Kawazoe, T. Tezuka, Keisuke Ishizawa et al. · 0 citations
Review Open access Sep 2026

Myositis-specific and myositis-associated autoantibodies in idiopathic inflammatory myopathies: An EASI survey on current clinical and laboratory practices

Objectives Detection of myositis-specific and myositis associated autoantibodies (MSA/MAA) aids in classification, diagnosis, and risk stratification of idiopathic inflammatory myopathies (IIM). To identify opportunities for harmonization, we assessed laboratory and clinical variability in IIM serological testing. Meth...

W. Vroemen, M. Dragon-Durey, Y. Allenbach et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.